Nerviano Medical Sciences is attending the AACR Annual Meeting, one of the the most important events in the cancer research calendar, which this year is taking place in Chicago from April 14th to 18th.
Specifically, researchers from Nerviano Medical Sciences are presenting preclinical data regarding four proprietary molecules:
- NMS-P088, a potent inhibitor of FLT3, KIT and CSF1R kinases;
- NMS-E668 a selective RET kinase inhibitor with high selectivity towards VEGFR2;
- NMS-P293, a PARP inhibitor with a unique profile, including high in vivo activity, lack of DNA trapping activity and high blood-brain barrier permiability;
- NMS-P945, an innovative and proprietary payload for antibody-drug conjugate (ADC) generation.
These scientific updates showcase Nerviano Medical Sciences's research strategies and capabilities, based on specialized drug discovery platforms with extensive intellectual property coverage, which together with our technologies and know-how result in the discovery and development of innovative therapeutic agents.
April 15, 2018, 1:00 PM - 5:00 PM Section 35. Session PO.ET01.01 - Antibody-Drug Conjugates: Agents and Technology. 734 / 1 – “Thienoindoles: New highly promising agents for antibody-drug conjugates generation”
April 15, 2018, 1:00 PM - 5:00 PM Section 37. Session PO.ET06.03 - Experimental Agents and Combinations for Hematologic Malignancies 1. 805 / 15 – “NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML”
April 17, 2018, 1:00 PM - 5:00 PM Section 36. Session PO.ET06.09 - Canonical Targets 1. 4785 / 14 – “NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET driven cancer models”
April 17, 2018, 1:00 PM - 5:00 PM Section 38. Session PO.ET06.01 - DNA Damage and Cell Cycle Regulation Experimental Therapeutics. 4843 / 12 – “NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma”